Anuva

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anuva

Quick Facts

Property Description
Active ingredient Diclofenac (as sodium or potassium salt)
Form Tablets, capsules, topical gel, solution for injection, suppositories
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Relief of pain, inflammation, and fever
Origin Synthetic (Phenylacetic acid derivative)

What Type of Medicine is Anuva and its Active Ingredient?

Anuva is a medicinal preparation whose active ingredient is Diclofenac, which is formally categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This pharmacological classification defines its fundamental role in addressing symptoms related to the body's inflammatory process.

The compound Diclofenac is a synthetic compound derived from phenylacetic acid. This unique structure enables its powerful physiological action as a cyclooxygenase (COX) inhibitor, interfering with the key enzymes that initiate signals for pain and swelling. Diclofenac is clinically recognized for its strong anti-inflammatory agent profile and its role in modulating inflammatory mediators. The drug's rapid onset of action in certain formulations is a key differentiating factor that supports its use when swift relief is needed.

Diclofenac's Primary Purpose and Available Forms

The overall general purpose of Anuva is to provide broad symptomatic relief by targeting the three main components of discomfort: pain, inflammation, and elevated body temperature or fever. By operating as an effective antipyretic agent and a potent analgesic agent, Diclofenac helps mitigate general malaise caused by these symptoms. For example, it is typically used to alleviate discomfort associated with chronic inflammatory conditions.

To accommodate different patient needs and routes of administration, Anuva (Diclofenac) is produced as a single active ingredient product in several distinct pharmaceutical preparations. These dosage form(s) commonly include oral options, such as tablets and capsules, alongside specialized preparations for topical gel application to the skin and solutions intended for injection. This comprehensive range of forms ensures versatile delivery of the active ingredient to exert its function as an established anti-rheumatic preparation, differentiating it from NSAIDs limited only to oral administration.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Anuva?

Possible Side Effects and Safety Information

The active ingredient in Anuva, Diclofenac, is an NSAID whose safety profile is officially documented by governmental regulatory authorities. Adverse reactions are formally classified by frequency and grouped according to the body system affected.

Frequency and System-Specific Adverse Reactions

Adverse effects listed as Common in regulatory documents often involve the Gastrointestinal (GI) and Nervous Systems. These include reactions such as headache, dizziness, nausea, vomiting, dyspepsia (indigestion), abdominal pain, flatulence, and transient elevations of liver enzymes. Skin effects like rash and pruritus (itching) are also commonly reported.

Documented Serious Systemic Risks

The official safety information highlights the potential for several rare but serious adverse reactions across major organ systems:

  • Serious Cardiovascular (CV) Thrombotic Events: The regulatory labeling notes a risk of serious CV events, including myocardial infarction (MI) and stroke, which may increase with the duration of use and can occur as early as the first weeks of treatment.
  • Serious Gastrointestinal Events: There is a documented risk of GI bleeding, ulceration, and perforation, which can occur at any time during use and may be fatal.
  • Hepatotoxicity: Severe hepatic reactions, including liver failure, have been reported.
  • Serious Skin Reactions: Rare, sometimes fatal, skin reactions such as Stevens-Johnson Syndrome (SJS) are listed, with the highest risk occurring early in the course of therapy.

Population and Restriction Notes

The safety profile includes restrictions for certain groups. Elderly patients are documented as being at greater risk for serious GI events. Diclofenac is formally contraindicated in patients with a history of asthma or allergic-type reactions to NSAIDs, in the setting of Coronary Artery Bypass Graft (CABG) surgery, and in individuals with established heart failure (NYHA II-IV) or active GI ulceration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official prescribing information documents the manifestations and required emergency actions for an Anuva (Diclofenac) overdose. Overdosage may initially present with common signs of NSAID toxicity, including epigastric pain, nausea, vomiting, and diarrhea. Other documented manifestations may affect the central nervous system, involving drowsiness, lethargy, headache, dizziness, confusion, and tinnitus.

Regulatory authorities classify certain outcomes as severe or life-threatening risks, including gastrointestinal bleeding, ulceration, and perforation, as well as seizures (convulsions) and acute renal failure. Coma and shock are documented as potential, rare consequences of massive ingestion.

Seek medical help right away for any suspected overdose. Additionally, seek emergency help immediately if a severe hypersensitivity or anaphylactic reaction occurs.

Treatment is explicitly defined as symptomatic and supportive care, as no specific antidotes are known to reverse the drug’s effects. Hospital management typically involves monitoring of vital signs and renal function, and may include procedures like oral activated charcoal or gastric lavage. Overdose consequences, particularly serious GI events, are noted to be more serious in elderly patients.

Therapeutic Uses of Anuva

Anuva (Diclofenac) is generally used across conditions presenting with systemic or localized discomfort and symptoms related to inflammatory or irritative states. The use of Anuva is relevant when supportive symptom management is appropriate, and it may provide supportive therapeutic benefit to ease the overall symptom burden.

The medication is commonly used to help with symptomatic relief in conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gouty arthritis, dysmenorrhea, and migraine attacks. This application is relevant in contexts involving heightened systemic burden, such as managing postoperative pain or inflammation from injuries.

“It plays a role in managing symptoms related to physical discomfort and easing manifestations that interfere with functional stability.”

Symptomatic Support for Pain and Inflammation

Anuva may contribute to improved comfort during periods of heightened symptoms by helping to address the specific clusters of pain, swelling, tenderness, and stiffness. This can generally support patients during episodes of heightened discomfort across various acute and chronic scenarios.

Regulatory References

  1. NIH MedlinePlus overview of Diclofenac uses

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Anuva (cabozantinib)

Regulatory documents establish specific rules defining who can and cannot use Anuva. Eligibility is determined primarily by the patient's acute clinical status, reproductive status, age, and organ function severity.

Absolute Exclusions (Contraindications and Permanent Discontinuation)

Classification Example Condition/Status
Contraindicated Known hypersensitivity to cabozantinib or its excipients.
Permanent Discontinuation Gastrointestinal perforation, Grade 4 fistula, hypertensive crisis, or a serious arterial thromboembolic event.

Restricted and Non-Recommended Use

Age-Related Eligibility: Anuva is approved for adults and for pediatric patients 12 years of age and older for certain indications. Use in younger children is not established.

Pregnancy and Lactation: Use is not recommended during pregnancy due to the risk of fetal harm. Women of reproductive potential must use effective contraception during treatment and for at least 4 months after the last dose. Breastfeeding should be discontinued during treatment and for 4 months afterward.

Organ Impairment: Use is not recommended in patients with severe hepatic impairment (Child-Pugh C) or severe renal impairment as safety and efficacy have not been established. Patients with moderate hepatic impairment require a dose reduction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Anuva (Diclofenac) has documented interaction patterns that are classified according to their official impact on pharmacodynamics and pharmacokinetics, as described in regulatory documents.

Documented Interaction Classifications

Classification Interacting Substance/Class Official Interaction Outcome
Pharmacodynamic Risk Anticoagulants, Antiplatelet Agents, SSRIs/SNRIs, Systemic Corticosteroids Increased additive risk of serious gastrointestinal bleeding.
Pharmacodynamic Antagonism ACE Inhibitors, ARBs, Diuretics May diminish antihypertensive or natriuretic effect; increased risk of renal deterioration.
Reduced Renal Clearance Lithium, Methotrexate Increases plasma concentrations of the co-administered drug.
Metabolic Exposure Alteration CYP2C9 Inhibitors (e.g., Voriconazole) Increases Diclofenac systemic exposure.

Interaction-Related Restrictions and Constraints

Co-administration is formally contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery. Other systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are generally avoided due to the potential for additive gastrointestinal risk. Diclofenac use is restricted for 8–12 days following mifepristone administration to avoid theoretical reduction of its effect. Furthermore, the official product information notes that use of alcohol increases the risk for serious gastrointestinal adverse events. Specific oral formulations may have reduced effectiveness when taken with food.

Mechanism of Action

Modulating Prostaglandin Synthesis

The drug primarily operates within the domain of eicosanoid synthesis by acting as a competitive inhibitor of Cyclooxygenase (COX) enzymes. By blocking the active sites of both COX-1 and, preferentially, COX-2, this mechanism significantly reduces the creation of pro-inflammatory and pyretic mediators, notably Prostaglandin E2 ( PGE2). This primary molecular step modifies the early part of the inflammatory cascade, leading to a functional attenuation of the signaling molecules involved in the physiological response.

Central Thermoregulation and Nociceptive Modulation

The mechanism extends to the central nervous system (CNS) and peripheral nerve function. Inhibition of PGE2 synthesis within the hypothalamus allows the central thermoregulatory set-point to be reset to its homeostatic value. Additionally, the drug engages non-COX pathways by modulating specific ion channels on nerve cell membranes ( K ATP and Na^+ channels), thereby modulating the electrical activity and attenuating the excitability of sensory neurons.

Mechanism Constraints on Physiological Homeostasis

As a constraint inherent to its mechanism, the necessary inhibition of the constitutive COX-1 enzyme results in the inhibition of prostaglandins that fulfill homeostatic functions. This secondary effect is associated with the reduced production of mediators that maintain the integrity of the gastric mucosal barrier and regulate renal blood flow under volume-depleted conditions.

Dosage and Administration Information

Anuva (Diclofenac) is administered through multiple official routes, including oral (tablets, capsules, powder), topical (gel, solution, patch), rectal (suppositories), and parenteral (intravenous infusion). The standard clinical principle for systemic use mandates employing the lowest effective dose for the shortest duration possible to achieve symptom control.

Dosing regimens are highly form-dependent. The typical systemic daily range for chronic management is often 100 mg to 150 mg, which may be taken in divided doses (e.g., two to three times daily) for immediate-release forms, or as a single dose for extended-release forms. The established maximum daily dose for oral administration must not be exceeded.

Specific administration rules govern proper usage. Oral delayed-release and extended-release tablets must be swallowed whole and must not be crushed, split, or chewed, as this compromises the intended release kinetics. The oral powder formulation, used for acute pain, must be dissolved in a small volume of water and consumed immediately on an empty stomach to support absorption.

For intravenous use, the solution requires dilution and buffering and must be administered as a slow infusion rather than a rapid injection. If a dose is missed, the standard protocol is to skip the missed dose and resume the regular schedule; doubling the subsequent dose is prohibited. Use in older adults requires caution, and safety and effectiveness are not established in children under 12 years of age for many forms.

Recent Clinical Evidence

Research evidence / Overview of studies for Anuva

Evidence for Symptom Management in Chronic Joint Conditions

The research base for Anuva relies on Randomized Controlled Trials (RCTs) and Meta-analyses, which are studies that pool data from many trials. This research explored conditions characterized by fluctuating symptoms and functional limitations, such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis. The populations typically included Adults and Older Adults diagnosed with these chronic conditions.

Studies report that the compound was observed in research exploring short-term symptom changes, where findings describe patterns observed in the studies related to changes in measured scores within the observed populations. Research also describes patient-reported experiences concerning symptoms. Long-term functional outcomes across different patient groups are not fully characterized, as follow-up durations were limited in many initial controlled trials. While evidence contributes to understanding symptom patterns, research does not determine whether an individual will respond similarly.

Evidence for Acute Pain and Inflammatory States

Research has evaluated the compound in contexts involving episodic symptom activity typical of acute pain states. Studies explored its use in settings like postoperative pain, dysmenorrhea (menstrual pain), acute gouty arthritis, and migraine attacks. These research scenarios typically involved very short-term, single-dose RCTs.

In these trials, studies examined outcomes describing episodic or acute changes, such as the time it took for patients to report changes in pain intensity. Studies report measurements related to the onset of changes in pain scores. A significant limitation in the evidence for acute pain is that the follow-up durations were limited; the results apply only to the populations studied. The very short observation periods provide limited information about symptom patterns beyond 24 hours.

What the Research Structure Does Not Fully Characterize

Research is ongoing, but the long-term effects are not fully established beyond the periods covered by major observational and extension studies. Specific limitations include that sample sizes were modest in some earlier trials, and data for certain groups with complex co-existing conditions remain insufficient. Studies are focused on symptomatic outcomes, and the evidence base provides limited insight into long-term physiological changes or disease progression, as that was not the primary focus of most studies. Therefore, findings describe group patterns, but research provides context and not individual predictions.

Key Studies & References Osteoarthritis: care and management (NICE Guideline CG177)

Frequently Asked Questions (FAQ)

Common questions about Anuva (FAQ)


Q: How quickly does Anuva start working?

Studies and official information indicate that the time it takes for Anuva to start working can vary based on the specific formulation. Forms designed for rapid use, such as the oral powder, are noted for quick absorption, and effects were reported in clinical studies as early as 30 minutes in certain formulations. Extended-release or topical forms typically have a slower onset due to their design.

Q: If I miss a day of Anuva, what should I expect?

Official regulatory instructions for a missed dose typically state that the patient should skip it and simply resume the regular schedule; doubling the subsequent dose is prohibited. Missing a dose may be associated with a temporary return of the pain and inflammation symptoms the medication addresses.

Q: Can Anuva be taken long-term?

Official safety warnings emphasize that Anuva should generally be used at the lowest effective dose for the shortest duration possible, as the risk of serious side effects may increase with long-term use. Despite this caution, it is prescribed for the long-term management of chronic conditions like arthritis, where periodic monitoring is an established component of its use.

Q: Is Anuva safe to use with common pain relievers?

Regulatory documents state that using Anuva with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including certain pain relievers like aspirin, should generally be avoided. This is due to a significantly increased risk of serious gastrointestinal bleeding. For pain relievers outside of the NSAID class, the drug label does not list an explicit contraindication.

Q: Does Anuva affect sleep patterns?

Official regulatory labels include certain central nervous system effects that could impact sleep. Side effects such as drowsiness and insomnia are noted in the official product information. Changes to sleep patterns are among the effects that official labeling suggests should be reported.

Q: Can Anuva be taken with herbal supplements?

Official drug labeling is focused primarily on interactions with other prescription medications and does not list every known herbal supplement. However, official regulatory guidance emphasizes the importance of a complete review of all concomitant medications and supplements, including herbals, as part of the clinical risk assessment.

Q: Can Anuva be split or crushed?

Specific administration rules must be followed. Delayed-release and extended-release tablets must always be swallowed whole and they must not be crushed, split, or chewed, as this action compromises the drug's intended release into the body. Instructions for other forms, such as immediate-release tablets, must be checked with the specific product information.

Q: Does taking Anuva require changes to diet or activity?

Specific administration constraints exist, such as certain oral forms needing to be taken on an empty stomach because food can reduce absorption. Additionally, topical forms require patients to avoid sun exposure on the treated area. No other specific general diet or activity changes are universally mandated in the official label.

Q: Is Anuva available over the counter?

While some low-strength topical forms (gels, patches) of Anuva (Diclofenac) may be available over the counter in certain areas, the systemic oral forms (tablets, capsules) have been restricted to prescription-only status in many countries. This is due to the potential risk of serious cardiovascular side effects.

Q: Is Anuva known to be habit-forming?

No. Anuva (Diclofenac) is categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is not classified as a controlled substance by regulatory bodies and is not considered to have a risk of physical dependence or being habit-forming.

Q: Are there any specific foods to avoid while using Anuva?

Official labeling does not typically list specific foods to avoid, but it is noted that certain oral formulations must be taken on an empty stomach. Taking these specific forms with food can significantly reduce the amount of the drug absorbed into the body.

Q: How does Anuva affect the liver or kidneys?

Official warnings indicate Anuva can affect both the liver and kidneys. The label warns of a risk of severe hepatotoxicity (liver damage), including liver failure. For kidneys, it can cause deterioration of function in some high-risk patients due to its effect on prostaglandins that help maintain proper renal blood flow.

Q: Why is Anuva restricted for certain age groups?

Regulatory restrictions exist because the safety and effectiveness are not established in children under 12 years of age for many forms of the drug. For older adults, they are documented to be at a greater risk for serious adverse events, particularly gastrointestinal events, necessitating the use of the lowest effective dose.

Q: Has Anuva been studied in older adults?

Yes, Anuva has been studied in populations that include older adults. While effectiveness may be similar to younger adults, official warnings indicate older patients may be at a greater risk for developing serious adverse events. Caution is advised, and the lowest possible dose is recommended for use in this group.

Q: Is Anuva considered a 'new' drug, or has it been around for a while?

The active ingredient in Anuva, Diclofenac, is a long-established medication. It was first approved by the FDA under a trade name in 1988, and it is now widely available in generic forms and various brand names.

Q: Can Anuva affect birth control effectiveness?

Official information generally indicates that Anuva (Diclofenac) is not expected to affect the effectiveness of hormonal contraceptives, including both the combined birth control pill and the progestogen-only pill.

Q: What are the most common reasons people stop taking Anuva?

While regulatory documents do not publish specific rankings of discontinuation reasons, serious adverse events (such as cardiovascular or gastrointestinal events) or common adverse reactions like gastrointestinal upset, dizziness, or headache are the types of events that often lead to withdrawal from clinical trials.

Q: Does Anuva change your mood or mental focus?

Official regulatory labels include psychiatric and nervous system side effects. These can include effects such as depression, anxiety, confusion, and irritability. Changes to mood or mental focus are among the adverse effects that official labeling suggests should be reported.

Q: Is there a risk of withdrawal symptoms when stopping Anuva?

Anuva is not associated with physical dependence or a formal withdrawal syndrome upon discontinuation. However, stopping the drug will naturally lead to a return of the pain and inflammation symptoms that the medication was treating.

Q: What studies support the use of Anuva in children?

Use in children under 12 years of age is largely not established due to a lack of sufficient studies. For the approved indication in pediatric patients 12 years of age and older, evidence is derived from trials showing effectiveness in treating conditions like Juvenile Idiopathic Arthritis in a subset of the pediatric population.

Q: Is it possible to be allergic to Anuva?

Yes. Anuva is formally contraindicated in patients with known hypersensitivity, which includes serious skin reactions, to Diclofenac or any components of the drug. It is also contraindicated in individuals who have a history of asthma or allergic-type reactions after taking aspirin or other NSAIDs.

Q: Does Anuva have a Black Box Warning?

Yes. Anuva (Diclofenac), like all systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), carries an FDA Boxed Warning (the highest safety alert). This warning highlights the serious risks of Cardiovascular Thrombotic Events (like heart attack and stroke) and Gastrointestinal Adverse Events (like bleeding and ulceration).

Q: How common are serious side effects with Anuva?

Official documents classify side effects by frequency. Common effects, such as headache and nausea, occur in 1% to 10% of patients. Serious events, such as GI bleeding or cardiovascular events, are listed as Rare or Infrequent, but they are documented as potentially severe.

Q: Is Anuva used for prevention or just treatment?

Anuva is approved for the treatment of pain and inflammation, meaning its function is to provide relief from the signs and symptoms of a condition. It is not approved for long-term prophylactic (preventive) therapy.

Q: What is the research status of Anuva for new uses?

Research into the uses of Diclofenac is continuous. Government health authorities regularly review scientific literature and clinical trials for new information on its safety, efficacy, and potential applications beyond its core established uses for pain and inflammation.

Q: Is the purpose of Anuva to treat symptoms or the underlying cause?

The purpose of Anuva (Diclofenac) is primarily to provide symptomatic relief by reducing pain, inflammation, and fever through its effect on prostaglandin production. It does not treat or cure the underlying cause of chronic diseases like arthritis.

Q: Can Anuva affect the results of lab tests?

Yes, Anuva (Diclofenac) can cause changes in lab test results. Elevations of liver enzymes are commonly reported. Other potential effects include changes in kidney function tests and certain hematologic parameters (blood cell counts).

Q: Is Anuva part of a class of drugs with known risks?

Yes. Anuva belongs to the class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This entire class of medications is known to carry documented serious adverse event risks, including cardiovascular thrombotic events and serious gastrointestinal events.

Q: Does Anuva contain any known allergens like gluten or lactose?

The inactive ingredients (excipients) in Anuva vary by formulation and manufacturer. However, some oral forms of Diclofenac are known to contain lactose. Patients should always consult the specific product's package insert to confirm the presence of gluten, lactose, or other potential allergens.

Q: What official information is available about Anuva's long-term safety?

Official safety information emphasizes that the risk of serious side effects, particularly cardiovascular events, may increase with the duration of use. The drug is used long-term for chronic conditions but requires regular re-evaluation and the use of the lowest effective dose for the shortest period possible.

How should Anuva be stored and disposed of?

How to Store and Dispose of Anuva (Diclofenac)

Storage and handling for Anuva must comply strictly with official regulatory specifications to maintain product quality.

Storage Conditions

Anuva tablets require storage at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and must not be stored above 30 C (86 F). The product must be protected from moisture and must be dispensed in a tight, light-resistant container, as defined in regulatory standards. For safety, Anuva must be stored out of the reach of children.

Handling and Disposal

Topical forms (gel or solution) require specific handling, including washing hands completely after application and avoiding sun exposure on the treated area. Unused or expired Anuva and its waste material must be disposed of in accordance with all local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anuva found in:

A-Z Index: